Gastrointestinal Cancer

Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.

The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.

Yu Sunakawa, MD, PhD, further discusses the early real-world data from the DELIVER trial with nivolumab in patients with gastric/GEJ cancer and provided insight into what future analyses will examine.

Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.

The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.

Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Yelena Y. Janjigian, MD, discusses updated results from the ​phase 2 DESTINY-Gastric01 trial​ in previously treated patients with HER2-positive gastric cancer.

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

The National Medical Products Administration in China has approved pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 as determined by an approved test, following disease progression on 1 prior line of systemic therapy.

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

The recent approval of nivolumab in combination with ipilimumab demonstrates the utility of dual immunotherapy for patients with hepatocellular carcinoma.

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

The FDA has granted a fast track designation to liposomal irinotecan for use in combination with 5-fluorouracil/leucovorin and oxaliplatin as a treatment for patients with previously untreated, unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma.

Brandon G. Smaglo, MD, FACP, discusses the future of immunotherapy in gastric cancer.

The FDA has granted an Orphan Drug designation to DKN-01 for the treatment of patients with gastric cancer or gastroesophageal junction cancer.

Jonathan Mizrahi, MD, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.

The FDA has approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Philip A. Philip, MD, PhD, FRCP, discusses challenges in pancreatic cancer and the emergence of devimistat in the treatment paradigm.

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.